Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2019032927) METHODS FOR PRODUCING GENETICALLY ENGINEERED CELL COMPOSITIONS AND RELATED COMPOSITIONS



Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2018/046149 735042013140
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
09 August 2018 09 August 2017
Applicant
JUNO THERAPEUTICS, INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     3A    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 35/17 (2015.01)i; A61K 39/00 (2006.01)i; A61K 39/395 (2006.01)i; A61K 39/44 (2006.01)i; C12N 5/0783 (2010.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K; C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2012129514 A1 (HUTCHINSON FRED CANCER RES [US]; RIDDELL STANLEY R [US]; HUDECEK MICHA) 27 September 2012 (2012-09-27)
1-105
examples 1-6
claims 1-38
(2)
X
REBECCA A. GARDNER ET AL, "Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults", BLOOD,Vol. 129, No. 25, 13 April 2017 (2017-04-13), page 3322-3331,
XP055509718
1-105
the whole document
Methods
figure 1
(3)
X
S. A. ALI ET AL, "T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma", BLOOD,Vol. 128, No. 13, 13 July 2016 (2016-07-13), page 1688-1700,
XP055334154
1-105
the whole document
Material and methods
(4)
X
CAMERON J. TURTLE ET AL, "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients", JOURNAL OF CLINICAL INVESTIGATION,Vol. 126, No. 6, 01 June 2016 (2016-06-01), page 2123-2138,
XP055402477
1-105
the whole document
Results
Methods
(5)
A
Alexey Bersenev, "Crude versus defined CAR T-cell therapy product", 01 May 2016 (2016-05-01),
Retrieved from the Internet:
URL:https://stemcellassays.com/2016/05/crude-versus-defined-car-t-cell-therapy-product/
XP055509727
[retrieved on  2018-09-25]
1-105
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2012129514 A1
27 September 2012
AU 2012230780 A1
AU 2016238963 A1
AU 2018204208 A1
BR 112013024395 A2
CA 2830953 A1
CN 103502438 A
CN 106074601 A
EP 2689010 A1
JP 6203705 B2
JP 2014510108 A
JP 2016183194 A
KR 20140023931 A
RU 2013147157 A
SG 193591 A1
SG 10201602253S A
US 2014314795 A1
WO 2012129514 A1
02 May 2013
03 November 2016
05 July 2018
20 September 2016
27 September 2012
08 January 2014
09 November 2016
29 January 2014
27 September 2017
24 April 2014
20 October 2016
27 February 2014
27 April 2015
30 October 2013
30 May 2016
23 October 2014
27 September 2012
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
26 September 2018
Date of mailing of the international search report:
19 October 2018
Authorized officer:
Bayer, Martin
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E